Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 13/20 | 0.67 |
| ▸ | CCKAR | P32238 | 8/20 | 0.59 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | BRD2 | P25440 | 1/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641969 | 0.93 | CCKBR (0.65) | CCKBRCCKARSENP1 | |
| SCHEMBL1574399 | 0.93 | CCKBR (0.65) | CCKBRCCKARSENP1 | |
| SCHEMBL8711252 | 0.93 | CCKBR (0.65) | CCKBRCCKARSENP1 | |
| Water SCHEMBL9229371 | 0.92 | CCKBR (0.64) | CCKBRCCKARSENP1 | |
| SCHEMBL644328 | 0.90 | CCKBR (0.62) | CCKBRCCKARBRD4BRD2BRD3 | |
| SCHEMBL1574149 | 0.90 | CCKBR (0.62) | CCKBRCCKARBRD4BRD2BRD3 | |
| SCHEMBL4698221 | 0.90 | CCKBR (0.59) | CCKBRCCKARSENP1 | |
| SCHEMBL1574220 | 0.90 | BRD4 (0.61) | CCKBRCCKARSENP1BRD4BRD2 | |
| SCHEMBL1574224 | 0.90 | BRD4 (0.61) | CCKBRCCKARSENP1BRD4BRD2 | |
| SCHEMBL4423335 | 0.90 | CCKBR (0.67) | CCKBRCCKARSENP1BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039616-B2 | Benzodiazepine derivatives for treating hepatitis C infection | ASTRAZENECA AB (SE) | 2011-10-18 | — | — | US | disclosed |
| US-20090318427-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1928465-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | Arrow Therapeutics Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007034127-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318427-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | CNR1, GABRA6, SIGMAR1 | CCKBR 170/4885CCKAR 81/4885SENP1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.